Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma

被引：39
|
作者：
Fragioudaki, M. [1 ]
Tsirakis, G. [1 ]
Pappa, C. A. [2 ]
Aristeidou, I. [1 ]
Tsioutis, C. [1 ]
Alegakis, A. [3 ]
Kyriakou, D. S. [4 ]
Stathopoulos, E. N. [5 ]
Alexandrakis, M. G. [1 ]
机构：
[1] Univ Hosp Heraklion, Dept Hematol, Iraklion 71110, Crete, Greece
[2] Venizel Hosp Heraklion, Dept Hematol, Iraklion, Greece
[3] Univ Crete, Sch Med, Iraklion, Greece
[4] Univ Hosp Larisa, Blood Bank, Larisa, Greece
[5] Univ Hosp Heraklion, Dept Pathol, Iraklion 71110, Crete, Greece
来源：
LEUKEMIA RESEARCH | 2012年 / 36卷 / 08期
关键词：
Multiple myeloma; Angiogenesis; Cytokines; BAFF; Prognosis; BONE-MARROW ANGIOGENESIS; B-LYMPHOCYTE STIMULATOR; MALIGNANT PLASMA-CELLS; NECROSIS-FACTOR FAMILY; NF-KAPPA-B; STAGING SYSTEM; MICROVESSEL DENSITY; CLINICAL-FEATURES; ACTIVATING FACTOR; HODGKIN-LYMPHOMA;
D O I：
10.1016/j.leukres.2012.03.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B-cell activating factor (BAFF) is a B-cell growth factor. We measured its serum levels and correlated them with parameters of disease activity, as serum levels of tumor necrosis factor-alpha and lactate dehydrogenase, bone marrow microvascular density and proliferating cell nuclear antigen expression, in 50 myeloma patients, in 22 of them in plateau phase and in 20 controls. All of them were higher in patients and in advanced disease while reduced in plateau phase. BAFF correlated with all the above markers. Higher BAFF levels predicted a shorter survival, suggesting an important prognostic marker and a possible therapeutic target in myeloma. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1004 / 1008
页数：5
相关论文
共 50 条
  • [1] Relationship between Circulating BAFF Serum Levels with Proliferating Markers in Patients with Multiple Myeloma
    Alexandrakis, Michael G.
    Roussou, Parascevi
    Pappa, Constantina A.
    Messaritakis, Ippokratis
    Xekalou, Athina
    Goulidaki, Nektaria
    Boula, Anna
    Tsirakis, George
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [2] CLINICAL AND PROGNOSTIC SIGNIFICANCE OF ELEVATED SERUM BAFF LEVELS IN MULTIPLE MYELOMA
    Tsirakis, G.
    Fragioudaki, M.
    Kaparou, M.
    Hatzivassili, A.
    Sfyridaki, K.
    Pappa, C.
    Kyriakou, D.
    Alexandrakis, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 387 - 387
  • [3] RELATIONSHIP BETWEEN CIRCULATING BAFF LEVELS WITH PROLIFERATION MARKERS IN PATIENTS WITH MULTIPLE MYELOMA
    Tsirakis, G.
    Fragioudaki, M.
    Boula, A.
    Spanoudakis, M.
    Kaparou, M.
    Kanellou, P.
    Papadakis, I.
    Alegakis, A.
    Pappa, C.
    Alexandrakis, M.
    HAEMATOLOGICA, 2012, 97 : 337 - 338
  • [4] Low levels of BAFF in the serum of patients
    Yilmaz, Vuslat
    Gungor-Tuncer, Ozlem
    Parman, Yesim
    Serdaroglu, Piraye
    Deymeer, Feza
    Sayuhan-Direskeneli, Guher
    NEUROMUSCULAR DISORDERS, 2006, 16 : S106 - S106
  • [5] Monocyte dysfunction in patients with multiple myeloma and lymphoplasmacytic disorders is related to serum paraprotein levels
    Mainwaring, CJ
    Williams, MA
    Singer, CRJ
    Lush, RJ
    Smith, JG
    Haynes, CL
    Kelsey, SM
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) : 948 - 954
  • [6] Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy
    Li, Zhaohui
    Chen, Ping
    Zhang, Ying
    Chen, Juan
    Zheng, Shanshan
    Li, Wenbin
    Tang, Lijun
    Liu, Yipeng
    Zhao, Na
    RENAL FAILURE, 2024, 46 (02)
  • [7] Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity
    M. G. Alexandrakis
    C. A. Pappa
    M. Kokonozaki
    A. Boula
    R. Vyzoukaki
    D. Staphylaki
    A. Papadopoulou
    N. Androulakis
    G. Tsirakis
    A. Sfiridaki
    Medical Oncology, 2015, 32
  • [8] Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity
    Alexandrakis, M. G.
    Pappa, C. A.
    Kokonozaki, M.
    Boula, A.
    Vyzoukaki, R.
    Staphylaki, D.
    Papadopoulou, A.
    Androulakis, N.
    Tsirakis, G.
    Sfiridaki, A.
    MEDICAL ONCOLOGY, 2015, 32 (03)
  • [9] Serum BAFF levels in patients with myasthenia gravis
    Kang, S.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S207 - S208
  • [10] Serum BAFF and APRIL levels in patients with PBC
    Migita, Kiyoshi
    Ilyassova, Bibigu
    Kovzel, Elena F.
    Nersesov, Alexander
    Abiru, Seigo
    Maeda, Yumi
    Komori, Atsumasa
    Ito, Masahiro
    Yano, Koji
    Yatsuhashi, Hiroshi
    Shimoda, Shinji
    Ishibashi, Hiromi
    Nakamura, Minoru
    CLINICAL IMMUNOLOGY, 2010, 134 (02) : 217 - 225
12345